Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 6 of 6 for “"GLP-1 analogues"”.

  1. The effectiveness of GLP-1 analogues compared to DPP-4 inhibitors for beta cell function and diabetes related complications among adults with type 2 diabetes: a systematic review and meta-analysis

    … (DPP-4) inhibitors and glucagon-like peptide-1(GLP-1) analogues, have shown favourable effects on beta cell function. The aim of this systematic review was to provide a comprehensive synthesis of randomised clinical studies comparing the effectiveness of GLP-1 analogues to DPP-4 inhibitors in …

    adelaide Repository record for The effectiveness of GLP-1 analogues compared to DPP-4 inhibitors for beta cell function and diabetes related complications among adults with type 2 diabetes: a systematic review and meta-analysis (opens in a new tab)

  2. The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on cell viability, ADAM10 maturation and the proteolysis of ADAM10 substrates in SH-SY5Y cells

    … has suggested that glucagon-like peptide-1 (GLP-1) analogues; Lixisenatide, Dulaglutide, Liraglutide, and Exenatide (Exendin-4), currently used to treat diabetes, may also be beneficial in the treatment of neurodegenerative conditions such as AD, as they have been shown to exert …

    lancaster Repository record for The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on cell viability, ADAM10 maturation and the proteolysis of ADAM10 substrates in SH-SY5Y cells (opens in a new tab)

  3. THE ROLE OF HYPOGLYCEMIC AGENTS IN AMELIORATING COGNITIVE FUNCTIONS AND PSYCHIATRIC SYMPTOMS: FROM THE PSYCHIATRIC PATIENT TO EVIDENCE-BASED AND PHARMACOEPIDEMIOLOGIC APPROACHES FOR SUPPORTING THE CLINICAL PRACTICE

    … and drug targeting Glucagon-Like Peptide-1 (GLP-1) are being proposed for psychiatric and cognitive treatments, although their use for non-diabetic purposes remains debated. Methods: The role of antidiabetic drugs in ameliorating psychiatric and cognitive functions was explored across various …

    milano Repository record for THE ROLE OF HYPOGLYCEMIC AGENTS IN AMELIORATING COGNITIVE FUNCTIONS AND PSYCHIATRIC SYMPTOMS: FROM THE PSYCHIATRIC PATIENT TO EVIDENCE-BASED AND PHARMACOEPIDEMIOLOGIC APPROACHES FOR SUPPORTING THE CLINICAL PRACTICE (opens in a new tab)

  4. Self-assembly and aggregation of glucagon-like peptide 1 and its analogues

    … industry. Glucagon-like peptide 1 (GLP-1) is a hormone that is used in the treatment of type-2 diabetes. However, GLP-1 has a short half-life *in vivo* and it is prone to aggregate which complicates its pharmaceutical usage. Strategies to overcome the short half-life *in vivo* …

    cambridge Repository record for Self-assembly and aggregation of glucagon-like peptide 1 and its analogues (opens in a new tab)

  5. Characterisation of L-cell secretory mechanisms and colonic enteroendocrine cell subpopulations

    … and systemic signals. Glucagon-like peptide-1 (GLP-1) is one such hormone secreted from so-called L-cells found in both the small and large intestines. GLP-1 exerts an anorexigenic effect and together with glucose- dependent insulinotropic polypeptide (GIP), restores postprandial normoglycaemia …

    cambridge Repository record for Characterisation of L-cell secretory mechanisms and colonic enteroendocrine cell subpopulations (opens in a new tab)

  6. Gut-brain axis: Central impact of gut peptides and metabolic drug on monoamine neurotransmission

    … and the stable glucagon-like-peptide-1 (GLP-1) receptor agonist exendin-4 as well as putative GLP-1 congener geniposide, can affect the electrical activity of dopamine neurons in the ventral tegmental area (VTA) and of pyramidal neurons in the prefrontal cortex (PFC), using single-unit …

    de-montfort Repository record for Gut-brain axis: Central impact of gut peptides and metabolic drug on monoamine neurotransmission (opens in a new tab)